1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Barry Cohen
Barry Cohen
Articles (108) 

Goldman Sachs Sets BioMarin Target 75% Above Current Price

The gene therapy company is expected to introduce hemophilia drug that is projected to generate revenue of $1.2 billion by 2024

February 04, 2020 | About:

With sales of $1.6 billion over the past year, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will get a hefty revenue boost with the introduction of its hemophilia A therapy, which is expected later this year.

Valrox is forecast to reach sales of more than $1.2 billion by 2024, according to pharmaceutical intelligence provider Evaluate. The San Francisco-based biotech’s application is currently being reviewed by regulators in the U.S. and Europe.

In anticipation of a 2020 launch, the company is gearing up manufacturing at its Novato, California plant, more than doubling capacity to 10,000 doses.

The upgrade is important “because first-mover advantage in gene therapy is fundamental in a sense that every time you treat a patient that patient is off the market,” BioMarin Chairman and CEO Jean-Jacques Bienaime said at the annual J.P. Morgan Healthcare Conference.

The company’s shares trade at about $86, a bit higher than the middle of its 52-week range. The 23 analysts offering 12-month price forecasts for have a median target of $113, with a high estimate of $159 and $77 on the low side, reported CNN Business. It is rated a buy.

Goldman Sachs (NYSE:GS) is one of those most bullish about BioMarin’s prospects. The company made the investment bank’s coveted Conviction List, according to an article on 24/7 Wall St. The list is made up of the firm’s top picks for high net worth and institutional accounts. Goldman’s objective for the shares is $159.

Goldman likes that the company posted solid earnings last year and, in addition to Valrox, is developing a treatment for achondroplasia, which causes dwarfism. The company also sells a number of drugs, including Palynziq, an enzyme-substitution therapy that treats phenylketonuria, a genetic disorder that affects the brain. Another factor might be built into Goldman’s price objective: the chance that BioMarin could be acquired, with Roche (RHHBY) mentioned as a likely suitor.


One of the company’s top sellers, Kuvan, which also treats phenylketonuria, does face generic competition by the end of 2020. But RBC Capital Markets analyst Kennen MacKay downplayed the impact in a note, according to a recent Barrons article. “We believe the market is already pricing in what we see as a very severe impact of genericization,” MacKay wrote, “And see upside to estimates arising from the potential of BMRN’s high-touch patient support efforts to retain patients.”

MacKay upgraded BioMarin to outperform from sector perform and set a new price target of $113, up from $111.

BioMarin is in the lead for hemophilia A treatments, but does face challenges from Roche acquisition Spark Therapeutics and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Early results from Sangamo’s studies indicate its gene therapy could be a formidable competitor.

Disclosure: The author holds no positions in any of the companies mentioned in this article.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

About the author:

Barry Cohen
Barry Cohen has nearly 40 years experience in communications and marketing, the majority in senior positions at large international health care companies, including Abbott Laboratories and Bayer Inc.

He has contributed to a number of financial websites, writing primarily about the stocks of health care companies.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by Barry Cohen

User Generated Screeners

pascal.van.garsseHigh FCF-M2
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)